The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Clinoril     2-[(3E)-6-fluoro-2-methyl-3- [(4...

Synonyms: Klinoril, Sulindal, sulindac, Arthrobid, Chibret, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clinoril


Psychiatry related information on Clinoril


High impact information on Clinoril

  • We also prospectively examined the prevalence of aberrant crypt foci in 11 subjects (4 normal subjects, 6 with adenoma, and 1 with cancer) before and after the administration of 100 mg of sulindac three times a day for 8 to 12 months and compared the results with those in 9 untreated subjects (4 normal subjects and 5 with adenoma) [6].
  • Furthermore, treating Apc delta716 mice with a novel COX-2 inhibitor reduced the polyp number more significantly than with sulindac, which inhibits both isoenzymes [7].
  • The phenotypic changes involving both increased adhesion to ECM and inhibition of apoptosis were reversed by sulindac sulfide (a COX inhibitor) [8].
  • In contrast, one week of treatment with sulindac did not affect renal prostacyclin synthesis or renal function in the other 10 patients, despite a marked inhibition of extrarenal cyclooxygenase activity [9].
  • In contrast, the absence of BAX completely abolished the apoptotic response to the chemopreventive agent sulindac and other nonsteroidal anti-inflammatory drugs (NSAIDs) [10].

Chemical compound and disease context of Clinoril


Biological context of Clinoril


Anatomical context of Clinoril


Associations of Clinoril with other chemical compounds


Gene context of Clinoril


Analytical, diagnostic and therapeutic context of Clinoril


  1. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., Booker, S.V., Robinson, C.R., Offerhaus, G.J. N. Engl. J. Med. (1993) [Pubmed]
  2. Nephrotic syndrome associated with sulindac. Lomvardias, S., Pinn, V.W., Wadhwa, M.L., Koshy, K.M., Heller, M. N. Engl. J. Med. (1981) [Pubmed]
  3. Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug. Bunning, R.D., Barth, W.F. JAMA (1982) [Pubmed]
  4. Pancreatitis after administration of sulindac. Lilly, E.L. JAMA (1981) [Pubmed]
  5. Auditory and visual hallucinations associated with sulindac: focus on prostaglandin synthesis and psychotic symptoms. Sabet-Sharghi, F., Camara, E.G., Stagno, S. Psychosomatics. (1990) [Pubmed]
  6. Aberrant crypt foci of the colon as precursors of adenoma and cancer. Takayama, T., Katsuki, S., Takahashi, Y., Ohi, M., Nojiri, S., Sakamaki, S., Kato, J., Kogawa, K., Miyake, H., Niitsu, Y. N. Engl. J. Med. (1998) [Pubmed]
  7. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans, J.F., Taketo, M.M. Cell (1996) [Pubmed]
  8. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Tsujii, M., DuBois, R.N. Cell (1995) [Pubmed]
  9. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. Ciabattoni, G., Cinotti, G.A., Pierucci, A., Simonetti, B.M., Manzi, M., Pugliese, F., Barsotti, P., Pecci, G., Taggi, F., Patrono, C. N. Engl. J. Med. (1984) [Pubmed]
  10. Role of BAX in the apoptotic response to anticancer agents. Zhang, L., Yu, J., Park, B.H., Kinzler, K.W., Vogelstein, B. Science (2000) [Pubmed]
  11. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs. Stern, R.S., Bigby, M. JAMA (1984) [Pubmed]
  12. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. Shureiqi, I., Chen, D., Lee, J.J., Yang, P., Newman, R.A., Brenner, D.E., Lotan, R., Fischer, S.M., Lippman, S.M. J. Natl. Cancer Inst. (2000) [Pubmed]
  13. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Laffi, G., Daskalopoulos, G., Kronborg, I., Hsueh, W., Gentilini, P., Zipser, R.D. Gastroenterology (1986) [Pubmed]
  14. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Giardiello, F.M., Casero, R.A., Hamilton, S.R., Hylind, L.M., Trimbath, J.D., Geiman, D.E., Judge, K.R., Hubbard, W., Offerhaus, G.J., Yang, V.W. Gastroenterology (2004) [Pubmed]
  15. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Agarwal, B., Rao, C.V., Bhendwal, S., Ramey, W.R., Shirin, H., Reddy, B.S., Holt, P.R. Gastroenterology (1999) [Pubmed]
  16. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. Shiff, S.J., Qiao, L., Tsai, L.L., Rigas, B. J. Clin. Invest. (1995) [Pubmed]
  17. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Pasricha, P.J., Bedi, A., O'Connor, K., Rashid, A., Akhtar, A.J., Zahurak, M.L., Piantadosi, S., Hamilton, S.R., Giardiello, F.M. Gastroenterology (1995) [Pubmed]
  18. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Arber, N., Han, E.K., Sgambato, A., Piazza, G.A., Delohery, T.M., Begemann, M., Weghorst, C.M., Kim, N.H., Pamukcu, R., Ahnen, D.J., Reed, J.C., Weinstein, I.B., Holt, P.R. Gastroenterology (1997) [Pubmed]
  19. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants. Carter, S.A. Lancet (1979) [Pubmed]
  20. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Spagnesi, M.T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A., Bianchini, F. Gastroenterology (1994) [Pubmed]
  21. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Jacoby, R.F., Cole, C.E., Hawk, E.T., Lubet, R.A. Gastroenterology (2004) [Pubmed]
  22. Sulindac and gastric mucosa. Porro, G.B., Petrillo, M., Caruso, E., Fumagalli, M. Lancet (1977) [Pubmed]
  23. Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin. Calin, A., Britton, M. JAMA (1979) [Pubmed]
  24. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A., Krishnadath, K.K., Lutzke, L.S., Burgart, L.J. Gastroenterology (2002) [Pubmed]
  25. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Wong, D.G., Spence, J.D., Lamki, L., Freeman, D., McDonald, J.W. Lancet (1986) [Pubmed]
  26. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Tsujii, M., Kawano, S., DuBois, R.N. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  27. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Rüschoff, J., Wallinger, S., Dietmaier, W., Bocker, T., Brockhoff, G., Hofstädter, F., Fishel, R. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  28. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Mahmoud, N.N., Bilinski, R.T., Churchill, M.R., Edelmann, W., Kucherlapati, R., Bertagnolli, M.M. Cancer Res. (1999) [Pubmed]
  29. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., Martucci, C., Guo, X.J., Ramonetti, J.T., Abreu-Goris, M., Newmark, H.L., Lipkin, M.L., DeCosse, J.J., Bertagnolli, M.M. Cancer Res. (1996) [Pubmed]
  30. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Rice, P.L., Beard, K.S., Driggers, L.J., Ahnen, D.J. Cancer Res. (2004) [Pubmed]
  31. Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers. Bresalier, R.S. Gastroenterology (2002) [Pubmed]
  32. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Cruz-Correa, M., Hylind, L.M., Romans, K.E., Booker, S.V., Giardiello, F.M. Gastroenterology (2002) [Pubmed]
WikiGenes - Universities